10 results about "Inosine monophosphate" patented technology

Provided herein is a eukaryotic cell expressing an exogenously introduced inosine 5'-monophosphate dehydrogenase (IMPDH) that is resistant to a purine biosynthesis inhibitor, uses thereof for producing therapeutic agents and treating a disease or disorder, as well as pharmaceutical compositions and methods of making thereof.

The present invention discloses an SNP molecular marker related to the inosine monophosphate content of blunt snout bream and its application. Such SNP molecular markers are base mutations at the 141st bp, 185th bp, 223rd bp, and 250th bp of the blunt snout bream ampd1 gene fragment sequence. Among them, the base at the 141st bp is A or T, the base at the 185th bp is A or C, the base at the 223rd bp is A or G, and the base at the 250th bp is A or G. When the SNP molecular marker of the present invention is used for assisted breeding or for correlation analysis of the inosine monophosphate content of blunt snout bream, blunt snout bream with high inosine monophosphate content, that is, a homozygous genotype variety, can be quickly and conveniently screened out. This not only lays a solid foundation for marker-assisted breeding selection of blunt snout bream (such as hybrid blunt snout bream and blunt snout bream), but also can improve the quality of blunt snout bream and enhance the production economic benefits.

The invention relates to the technical field of biologic detection of metabolomics, in particular to an OSAHS metabolism marker, a diagnosis model and application of the OSAHS metabolism marker and the diagnosis model. The metabolic marker comprises a red blood cell metabolite and / or a plasma metabolite; erythrocyte metabolites comprise L-aspartic acid, D-ribose-5-diphosphoric acid, cadaverine, 12, 13-epoxy octadecenoic acid, L-arginine, N-acetylmethionine, 5-hydroxyeicosatetraenoic acid, 13-oxo-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 9, 10-tetrahydroxy-9Z, 10-tetrahydroxy-9Z, the component A is one or more of 11E-octadecadienoic acid, inosine monophosphate, nicotinamide, alpha-lactose, sphingosine, hydroxy octadecadienoyl or glyceraldehyde-3-phosphoric acid; the plasma metabolite is prepared from one or more of fumaric acid, cadaverine, L-aspartic acid, malic acid, sphingosine-1-phosphoric acid, L-arginine, cysteine-S-sulfate, thiosulfate, gamma-glutamyl alanine, galacturonic acid or vitamin B2.

This invention provides a kit for the simultaneous detection of nine flavor nucleotides in livestock and poultry products. The flavor nucleotides are cytidine monophosphate, uridine monophosphate, guanylic acid, inosine monophosphate, adenosine monophosphate, hypoxanthine, inosine, adenosine diphosphate, and adenosine triphosphate. The kit includes: a high-concentration extraction reagent, a standard curve solution, a high-concentration phosphate buffer solution, pH adjustment solution A, and pH adjustment solution B. The high-concentration extraction reagent is perchloric acid; the standard curve solution is a mixed solution of the nine flavor nucleotides; the high-concentration phosphate buffer solution is a solution of potassium dihydrogen phosphate and dipotassium hydrogen phosphate; pH adjustment solution A is sodium hydroxide; and pH adjustment solution B is phosphate. This invention also provides a method for the simultaneous detection of the nine flavor nucleotides using the above kit. This invention enables the simultaneous determination of the content of nine flavor nucleotides in livestock and poultry products. The method is simple, rapid, accurate, and sensitive, and can be used for batch determination, showing good prospects for practical application.

The present application relates to inosine monophosphate dehydrogenase (IMPDH) inhibitors for treating or preventing brain metastasis of a cancer For example, the IMPDH inhibitors are compounds of Formula I.

The present disclosure relates to a novel protein variant having an activity of exporting 5′-inosine monophosphate, a microorganism comprising the protein variant, and a method for preparing 5′-inosine monophosphate using the microorganism.

Provided herein are eukaryotic cells that express an exogenously introduced inosine 5 '-monophosphate dehydrogenase (IMPDH) that is resistant to purine biosynthesis inhibitors, uses of the enzyme in the production of therapeutic drugs and in the treatment of diseases or conditions, as well as related pharmaceutical compositions and methods of preparation thereof.

The present invention provides a cell including a recombinant DNA molecule including a first nucleic acid sequence encoding at least one first polypeptide being an enzyme selected from: inosine monophosphate dehydrogenase (Impdh), guanosine monophosphate synthetase (gmps), nucleotidase 5C (nt5c), polynucleotide phosphorylase (Pnp), or any combination thereof. Further provided is a method of using the cell of the invention, such as for synthesizing guanine.

The invention relates to the technical field of metabolome biologic detection, in particular to a metabolic marker for glaucoma diagnosis, a screening method, a diagnosis model and application of the metabolic marker. The metabolism markers comprise an erythrocyte metabolism marker and a plasma metabolism marker; the red blood cell metabolism marker comprises one or more of phosphate, pyrophosphoric acid, O-decenoyl-L-carnitine, hydroxy octadecadienoyl carnitine, inosine monophosphate, inosine diphosphate, malic acid, fumaric acid, D-erythritol-4-phosphoric acid, indole-3-acetaldehyde, cadaverine, hypoxanthine, ornithine, arginine and tyrosine; the plasma metabolism marker comprises one or more of sphingosine 1 phosphate, pyruvic acid, allantoate, 2-ketoglutaric acid, 5-oxoproline, malic acid, ornithine, fumarate, 5-L-glutamyl-L-glutamine, catechol-3-sulfonic acid, achloroanthocyanidin, L-aspartic acid, spermine, L-arginine or 5-hydroxyisouric acid.

RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-3010 and compositions, methods, and uses thereof.